Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular Tumour Boards and Precision Medicine in Czech Oncology Centres

Molecular Tumour Boards and Precision Medicine in Czech Oncology Centres Molecular Tumour Boards and Precision Medicine in Czech Oncology CentresAdela Bartova1, Barbora Rihova2Faculty of Medicine, Department of Pharmacology, Masaryk University, Brno, Czech Republic* E-mail: adela.bartova@med.muni.czAbstractThe success and clinical response of patients to cancer treatment depends on the ability to identify somatic mutations associated with the tumour—the so-called mutation charge, according to which we can better target and individualise treatment. Next-generation sequencing (NGS) has become a revolutionary method for decoding the order of individual nucleotides and DNA fragments. Sequencing the human genome can be done much faster at present, the cost of sequencing is still falling, and insurance companies are also gradually adding this procedure to their reimbursement list. NGS has opened up completely new possibilities in therapeutic, diagnostic, and screening procedures at the level of individual patients, and not only in oncology. Groups of experts who consult on individual cases and the results of NGS with a certain regularity were formed to decide on personalised oncological care. Internationally, we can call them molecular tumour boards (MTBs), and the Czech Republic is not lagging in creating these groups. Large oncology centres and university hospitals approach precision medicine, and at the same time, they are aware of the need to share http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Facultatis Pharmaceuticae Universitatis Comenianae de Gruyter

Molecular Tumour Boards and Precision Medicine in Czech Oncology Centres

Acta Facultatis Pharmaceuticae Universitatis Comenianae , Volume 69 (s1): 28 – Jul 1, 2022

Molecular Tumour Boards and Precision Medicine in Czech Oncology Centres

Acta Facultatis Pharmaceuticae Universitatis Comenianae , Volume 69 (s1): 28 – Jul 1, 2022

Abstract

Molecular Tumour Boards and Precision Medicine in Czech Oncology CentresAdela Bartova1, Barbora Rihova2Faculty of Medicine, Department of Pharmacology, Masaryk University, Brno, Czech Republic* E-mail: adela.bartova@med.muni.czAbstractThe success and clinical response of patients to cancer treatment depends on the ability to identify somatic mutations associated with the tumour—the so-called mutation charge, according to which we can better target and individualise treatment. Next-generation sequencing (NGS) has become a revolutionary method for decoding the order of individual nucleotides and DNA fragments. Sequencing the human genome can be done much faster at present, the cost of sequencing is still falling, and insurance companies are also gradually adding this procedure to their reimbursement list. NGS has opened up completely new possibilities in therapeutic, diagnostic, and screening procedures at the level of individual patients, and not only in oncology. Groups of experts who consult on individual cases and the results of NGS with a certain regularity were formed to decide on personalised oncological care. Internationally, we can call them molecular tumour boards (MTBs), and the Czech Republic is not lagging in creating these groups. Large oncology centres and university hospitals approach precision medicine, and at the same time, they are aware of the need to share

Loading next page...
 
/lp/de-gruyter/molecular-tumour-boards-and-precision-medicine-in-czech-oncology-iu3SmPk7CF

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
de Gruyter
Copyright
© 2022 Published by Sciendo
ISSN
1338-6786
eISSN
2453-6725
DOI
10.2478/afpuc-2022-0008
Publisher site
See Article on Publisher Site

Abstract

Molecular Tumour Boards and Precision Medicine in Czech Oncology CentresAdela Bartova1, Barbora Rihova2Faculty of Medicine, Department of Pharmacology, Masaryk University, Brno, Czech Republic* E-mail: adela.bartova@med.muni.czAbstractThe success and clinical response of patients to cancer treatment depends on the ability to identify somatic mutations associated with the tumour—the so-called mutation charge, according to which we can better target and individualise treatment. Next-generation sequencing (NGS) has become a revolutionary method for decoding the order of individual nucleotides and DNA fragments. Sequencing the human genome can be done much faster at present, the cost of sequencing is still falling, and insurance companies are also gradually adding this procedure to their reimbursement list. NGS has opened up completely new possibilities in therapeutic, diagnostic, and screening procedures at the level of individual patients, and not only in oncology. Groups of experts who consult on individual cases and the results of NGS with a certain regularity were formed to decide on personalised oncological care. Internationally, we can call them molecular tumour boards (MTBs), and the Czech Republic is not lagging in creating these groups. Large oncology centres and university hospitals approach precision medicine, and at the same time, they are aware of the need to share

Journal

Acta Facultatis Pharmaceuticae Universitatis Comenianaede Gruyter

Published: Jul 1, 2022

There are no references for this article.